Sono-Tek (SOTK) missed fiscal second-quarter expectations on both lines. EPS was $0.02 against a $0.05 consensus, a 60.0% shortfall. Revenue of $5.23 million came in 7.9% below the $5.68 million estimate. Earnings fell 33.3% year over year, and revenue grew just 1.3%, a clear slowdown from the 6% first-half pace, which implies a much stronger first quarter. Yet the quarter's significance lies almost entirely outside it. A record $7.19 million post-quarter order and a rebuilding backlog give management its best visibility in at least a year, though almost all of it lands in fiscal 2028. That is the central tension: a soft current quarter and unchanged guidance set against a forward picture that materially improved.
The quality of the quarter deserves scrutiny. Gross margin expanded to 53% from 50%, but management attributed it to an "unusually favorable product and geographic mix." That mix was a heavily U.S. medical quarter, with U.S. and Canada sales up 35% while APAC fell 45% and EMEA fell 33%. Even with that tailwind, operating income slipped 9% to $382,000. Operating expenses rose to $2.39 million from $2.17 million, led by a roughly 15% jump in marketing and selling. Net income of $366,000 benefited from nearly doubled interest income on the company's growing cash pile, which offset a higher tax bill. First-half figures look far better: operating income rose 41% and gross margin reached 55%. Still, the second-quarter trajectory was flatter than the six-month totals suggest.
Beneath the surface, the business continues to rotate hard toward medical. Medical sales rose 209% to $3.11 million in the quarter and 289% to $7.05 million for the half. That growth builds on a 54% gain in fiscal 2026 and was driven by drug-coated balloon and specialty stent systems as customers move into commercial production. Alternative energy collapsed 85% in the first half, which management tied to U.S. policy shifts in green hydrogen, electrolysis and fuel cells. Electronics also declined. In-line coating systems fell 14% for the half against last year's six high-priced solar systems worth $4.42 million. The quarter shows a company that has replaced one growth engine with another, but one still exposed to large-order lumpiness.
The forward catalysts are substantive. Backlog reached $9.51 million at August 31, up 23% sequentially. That marks a sharp contrast with the weak bookings flagged on the prior call. After quarter end came three orders totaling about $7.19 million: ten production systems for an existing alternative-energy customer across three sites. Notably, the order came from the very end market that is otherwise shrinking. Combined with a $3.6 million-plus medical diagnostic line order, these programs represent more than $10.79 million of backlog, mostly for fiscal 2028.
Management responded by pulling forward its capacity plans:
- Phase one moves up to December/January, with roughly $700,000 of capex lifting capacity from about $27 million to $33-36 million.
- A second phase would reach about $44-45 million.
- Early planning extends to roughly $85 million, possibly including a second site in South Carolina.
Newer threads include a defense/optics vertical, a 300mm semiconductor push and an expanding forward-deployed engineering team. Cash of $17.7 million with no debt funds all of this comfortably.
Bears have legitimate ammunition. Fiscal 2027 guidance stayed at flat-to-modest growth, with no raise despite the record order. Management also explicitly warned that third- and fourth-quarter gross margins may be less attractive without similar high-value U.S. shipments. Opex will keep climbing ahead of fiscal 2028 revenue, so the near-term earnings line could stay pressured even as backlog swells. Customer deposits also declined to $2.32 million from $3.07 million at fiscal year-end.
The market setup is more complicated than the miss implies. Shares closed at $7.12 ahead of the report, up 28.8% from the open after the prior release and nearly 49% above the 200-day moving average. They sat within 5% of a $7.48 inter-earnings and 52-week high set October 9. That run is dramatic considering the stock touched a quarterly low of $4.25 as recently as mid-September. Price trend and AVWAP readings remain positive. Investor sentiment moved the other way, falling sharply from -0.15 to -0.66, a substantial deterioration into firmly negative territory. A stock trading near its highs with deeply skeptical sentiment entered the report priced for the forward story rather than the quarter itself. That leaves it vulnerable if investors refocus on the miss, the margin warning and the unchanged guidance.
The bottom line is that Sono-Tek delivered a disappointing second quarter: earnings and revenue both missed, growth stalled and operating income declined. Meanwhile, the call materially strengthened the fiscal 2028 narrative through a record order, a rebuilt backlog and an accelerated capacity plan. Investors are being asked to look past a likely softer second half to that payoff. After a steep run toward 52-week highs, the stock offers little cushion if near-term execution or margins disappoint.